Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Filter articles using the following links
Financial press releases
Events & presentations
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
10 May 2023
GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023
21 April 2023
GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update
20 April 2023
GenSight Biologics Withdraws its EMA Application for LUMEVOQ®
04 April 2023
GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings
24 March 2023
GenSight Biologics Reports Full Year 2022 Consolidated Financial Results
15 March 2023
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
13 March 2023
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
10 March 2023
GenSight Biologics to Present at Upcoming Medical Conferences
09 March 2023
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
07 March 2023
GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines
View previous 9 articles
1
2
3
4
5
6
7
8
9
10
…
40
View next 9 articles
Go back to the page of the page